Search Result

Isoforms Recommended:	Lck

Results for "

LCK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AAK1 (1) Apoptosis (14) Aurora Kinase (2) Autophagy (3) Bcr-Abl (1) BCRP (1) Btk (1) c-Fms (1) c-Kit (4) c-Met/HGFR (2) CaMK (1) CDK (1) EGFR (3) FAK (1) Ferroptosis (1) FGFR (6) FLT3 (6) Fungal (1) GSK-3 (1) Interleukin Related (1) Itk (1) JAK (2) LIM Kinase (LIMK) (1) LRRK2 (1) MAP4K (1) Mitophagy (2) Organoid (2) p38 MAPK (4) PDGFR (7) PERK (2) PKC (1) PROTACs (1) Raf (1) Salt-inducible Kinase (SIK) (1) Small Interfering RNA (siRNA) (1) Src (34) Syk (8) TAM Receptor (1) Trk Receptor (1) ULK (1) VEGFR (7) Wee1 (1)
By Research Areas:	Cancer (41) Cardiovascular Disease (2) Infection (1) Inflammation/Immunology (23)

By Targets:

AAK1 (1)

Apoptosis (14)

Aurora Kinase (2)

Autophagy (3)

Bcr-Abl (1)

BCRP (1)

Btk (1)

c-Fms (1)

c-Kit (4)

c-Met/HGFR (2)

CaMK (1)

CDK (1)

EGFR (3)

FAK (1)

Ferroptosis (1)

FGFR (6)

FLT3 (6)

Fungal (1)

GSK-3 (1)

Interleukin Related (1)

Itk (1)

JAK (2)

LIM Kinase (LIMK) (1)

LRRK2 (1)

MAP4K (1)

Mitophagy (2)

Organoid (2)

p38 MAPK (4)

PDGFR (7)

PERK (2)

PKC (1)

PROTACs (1)

Raf (1)

Salt-inducible Kinase (SIK) (1)

Small Interfering RNA (siRNA) (1)

Src (34)

Syk (8)

TAM Receptor (1)

Trk Receptor (1)

ULK (1)

VEGFR (7)

Wee1 (1)

By Research Areas:

Cancer (41)

Cardiovascular Disease (2)

Infection (1)

Inflammation/Immunology (23)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12072

Lck Inhibitor 1 Publications Verification	Src	Inflammation/Immunology
Lck Inhibitor is a potent, orally active Lck (lymphocyte specific kinase) inhibitor with IC₅₀s of 7, 2.1, 4.2 and 200 nM for Lck, Lyn, Src and Syk kinases, respectively. Lck Inhibitor shows >1000-fold selectivity for Lck over MAPK, CDK and RSK family representatives. Lck Inhibitor inhibits T cell proliferation and in vivo models of arthritis .

HY-163278

Lck-IN-2	Src Apoptosis	Cancer
Lck-IN-2 (compound 12a) is an inhibitor of Lymphocyte-specific protein tyrosine kinase (Lck) with IC₅₀ of 10.6 nM. Lck-IN-2 reveals efficacy in colon cancer cells with GI₅₀s of 0.24-1.26 μM. Lck-IN-2 exhibits an apoptotic effect in Colo201 cells .

HY-162291

Lck-IN-3	Src Apoptosis	Cancer
Lck-IN-3 (compound 7m) is an *LCK* inhibitor targeting acute lymphoblastic leukemia (ALL) that inhibits LCK phosphorylation. Lck-IN-3 can induce cell cycle arrest in the G2/M phase, leading to apoptosis in ALL cells .

HY-112335

Lck Inhibitor III	Src Interleukin Related	Cancer
Lck Inhibitor III (compound 12h) is a potent *Lck* inhibitor, with an IC₅₀ of 867 nM. Lck Inhibitor III inhibits IL-2 synthesis in Jurkat cells, with an IC₅₀ of 1.270 μM .

HY-138202

Lck-IN-1

Src Inflammation/Immunology

Lck-IN-1 is a potent lymphocyte protein tyrosine kinase (Lck) inhibitor extracted from patent WO2007013673A1, example 48 .

Lck-IN-1	Src	Inflammation/Immunology
Lck-IN-1 is a potent lymphocyte protein tyrosine kinase *(Lck)* inhibitor extracted from patent WO2007013673A1, example 48 .

HY-10644

Lck inhibitor 2	Src	Inflammation/Immunology
Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively

HY-RS07550

LCK Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
LCK Human Pre-designed siRNA Set A contains three designed siRNAs for LCK gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

LCK Human Pre-designed siRNA Set A LCK Human Pre-designed siRNA Set A

HY-12299

WH-4-023 4 Publications Verification Dual LCK/SRC inhibitor	Src	Cancer
WH-4-023 is a potent and selective dual *Lck/Src* inhibitor with IC₅₀ of 2 nM/6 nM for Lck and Src kinase respectively; little inhibition on p38α and KDR.

HY-P3279

EPQpYEEIPIYL 1 Publications Verification	Src	Cancer
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .

HY-10256A

Adezmapimod hydrochloride Maximum Cited Publications 400 Publications Verification SB 203580 hydrochloride; RWJ 64809 hydrochloride	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) hydrochloride is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod hydrochloride inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod hydrochloride is an autophagy and mitophagy activator .

HY-W062835

CGP77675	Src	Cancer
CGP77675 is an orally active and potent inhibitor of Src family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀s of 5-20 and 40 nM, respectively), and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity .

HY-10256

Adezmapimod Maximum Cited Publications 400 Publications Verification SB 203580; RWJ 64809	Organoid p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator .

HY-W062835A

CGP77675 hydrate	Src	Cancer
CGP77675 hydrate is an orally active and potent inhibitor of Src family kinases. CGP77675 hydrate inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src (IC₅₀s of 5-20 and 40 nM, respectively),and also inhibits Src, EGFR, KDR, v-Abl, and Lck with IC₅₀s of 0.02, 0.15, 1.0, 0.31, and 0.29 μM, respectively. Anticancer activity .

HY-108318

RK-24466 KIN 001-51	Src	Cardiovascular Disease Inflammation/Immunology
RK-24466 (KIN 001-51) is a potent and selective *Lck* inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC₅₀s of less than 1 and 2 nM, respectively.

HY-11011

A-770041 4 Publications Verification	Src	Inflammation/Immunology
A-770041 is a selective and orally active Src-family *Lck* inhibitor. A-770041 inhibits Lck with an IC₅₀ value of 147 nM with the presence of 1 mM ATP. A-770041 shows 300-fold selective to Lck over Fyn, the other Src family kinase involved in T-cell signaling. A-770041 can be used for the research of acute rejection .

HY-13804

PP1 5+ Cited Publications AGL 1872; EI 275	Src Apoptosis	Cancer
PP1 is a potent, and Src family-selective tyrosine kinase inhibitor with IC₅₀ of 5 and 6 nM for Lck and Fyn, respectively.

HY-13805

PP2

35+ Cited Publications

AGL 1879
Src Cancer

PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC₅₀s of 4 and 5 nM for Lck and Fyn, respectively.

PP2 35+ Cited Publications AGL 1879	Src	Cancer
PP2 is a reversible and ATP-competitive Src family kinases inhibitor with IC₅₀s of 4 and 5 nM for *Lck* and Fyn, respectively.

HY-15764A

A 419259 trihydrochloride 2 Publications Verification RK 20449 trihydrochloride	Src Apoptosis	Cancer
A 419259 trihydrochloride is a Src family kinases inhibitor with IC₅₀s of 9 nM, 3 nM and 3 nM for Src, *Lck* and Lyn, respectively .

HY-P1377

Caffeic acid-pYEEIE

Src Inflammation/Immunology

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .
HY-P1377A

Caffeic acid-pYEEIE TFA

Src Inflammation/Immunology

Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

Caffeic acid-pYEEIE	Src	Inflammation/Immunology
Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

Caffeic acid-pYEEIE TFA	Src	Inflammation/Immunology
Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

HY-101053

Src Inhibitor 1 5+ Cited Publications Src Kinase Inhibitor 1; Src-l1	Src	Cancer
Src Inhibitor 1 is a potent, ATP-competitive and selective dual site Src tyrosine kinase inhibitor with IC₅₀ values of 44 nM for Src and 88nM for Lck.

HY-108485

Damnacanthal	Src Apoptosis Fungal	Infection Inflammation/Immunology Cancer
Damnacanthal is an anthraquinone isolated from the root of Morinda citrifolia. Damnacanthal is a highly potent, selective inhibitor of p56 ^lck tyrosine kinase activity. Natural Damnacanthal inhibits p56 ^lck autophosphorylation and phosphorylation of exogenous substrates with IC₅₀s of 46 nM and 220 nM, respectively. Damnacanthal is a potent inducer of apoptosis with anticancer activity. Damnacanthal also has antinociceptive, anti-inflammatory effects in mice and anti-fungal activity against *Candida albicans* .

HY-15764

A 419259 2 Publications Verification RK-20449	Src Apoptosis	Cancer
A 419259 is a broad-spectrum pyrrolo-pyrimidine inhibitor, has high selectivity towards the Src family. A 419259 shows inhibitory effect for Src, *Lck* and Lyn with IC₅₀ of 9 nM, <3 nM and <3 nM, respectively .

HY-10234A

Saracatinib difumarate 25+ Cited Publications AZD0530 difumarate	Src	Cancer
Saracatinib (AZD0530) difumarate is a potent Src inhibitor with IC50 values of 2.7-11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr and Blk, and is selective for other tyrosine kinases. .

HY-10234

Saracatinib 25+ Cited Publications AZD0530	Src Autophagy	Cancer
Saracatinib (AZD0530) is a potent Src family inhibitor with IC₅₀s of 2.7 to 11 nM for c-Src, *Lck, c-YES, Lyn, Fyn, Fgr, and Blk*. Saracatinib shows high selectivity over other tyrosine kinases .

HY-15590

AZ-23 3 Publications Verification AZ23; AZ 23	Trk Receptor	Cancer
AZ-23 is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC₅₀s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.

HY-13038A

Fostamatinib 5+ Cited Publications R788	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib (R788) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-13038

Fostamatinib Disodium 5+ Cited Publications R788(Disodium)	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib Disodium (R788 Disodium) is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-13038B

Fostamatinib disodium hexahydrate 5+ Cited Publications R788 disodium hexahydrate	Syk FLT3	Inflammation/Immunology Cancer
Fostamatinib (R788) disodium hexahydrate is the oral proagent of the active compound R406 . R406 is an orally available and competitive Syk/FLT3 inhibitor with a K_i of 30 nM and an IC₅₀ of 41 nM . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-15764G

A 419259 RK-20449	Src Apoptosis	Cancer
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC₅₀s of 9 nM, <3 nM, and <3 nM, respectively .

HY-146672

ITK inhibitor 6	Itk	Cancer
ITK inhibitor 6 (compound 43) is a potent and selective ITK inhibitor with IC₅₀s of 4 nM, 133 nM, 320 nM, 2360 nM, 155 nM for ITK, BTK, JAK3, EGFR, LCK, respectively. ITK inhibitor 6 inhibits phosphorylation of PLCγ1 and ERK1/2. ITK inhibitor 6 shows antiproliferative activities .

HY-12847

CCT241161	Raf Src Apoptosis	Cancer
CCT241161 is an orally active pan-RAF inhibitor with IC₅₀s of 3, 6, 10, 15 and 30 nM for *LCK, CRAF, SRC, V600E-BRAF* and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity .

HY-18307

SYN1143	c-Met/HGFR	Cancer
SYN1143 is a potent, selective and orally active dual inhibitor of c-Met/RON, with IC₅₀s of 4 and 9 nM, respectively. SYN1143 has weak inhibitory activity on *Lck, Tie2, Src, and BTK* with IC₅₀s ranging from 160 to 710 nM. SYN1143 can be used for the research of cancers that RON and c-Met are activated .

HY-18302

c-Kit-IN-5-1	c-Kit	Inflammation/Immunology
c-Kit-IN-5 is potent inhibitor of c-Kit, with IC₅₀s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over KDR, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties .

HY-18010

PCI 29732 3 Publications Verification	Btk BCRP	Inflammation/Immunology
PCI 29732 is a potent, orally active, reversible BTK inhibitor with K_i ^app values of 8.2, 4.6, and 2.5 nM for BTK, Lck and Lyn, respectively. PCI 29732 shows only modest inhibitory activity against Itk, another Tec family kinase. PCI 29732 inhibits the function of ABCG2 by competitively binding to the ATP-binding site of ABCG2 .

HY-12067

R406 20+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 reduces immune complex-mediated inflammation . R406 also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-10185

TG 100572 Hydrochloride 2 Publications Verification	Src VEGFR FGFR PDGFR	Inflammation/Immunology
TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-10184

TG 100572	Src VEGFR PDGFR FGFR	Cancer
TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

HY-132150A

HPK1-IN-2 dihydrochloride	MAP4K FLT3 Src	Cancer
HPK1-IN-2 dihydrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC₅₀<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride also inhibits Lck (0.05 µΜ<IC₅₀<0.5 µΜ) and Flt3 (IC₅₀<0.05 µΜ) kinase activities .

HY-10204

OSI-930 4 Publications Verification	c-Kit VEGFR c-Fms Apoptosis	Cancer
OSI-930 is an orally selective inhibitor of Kit, KDR and CSF-1R (c-Fms) with IC₅₀s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits Flt-1, c-Raf, *Lck* and low activity against PDGFRα/β, Flt-3 and Abl. OSI-930 has antitumor activity .

HY-18303

AMG-47a 2 Publications Verification	Src VEGFR p38 MAPK JAK	Inflammation/Immunology
AMG-47a is a potent and orally active lymphocyte-specific protein tyrosine kinase (Lck) inhibitor, with an IC₅₀ of 0.2 nM. AMG-47a also inhibits VEGF2, p38α, Jak3 and MLR and IL-2 with IC₅₀s of 1 nM, 3 nM, 72 nM, 30 nM and 21 nM, respectively. AMG-47a has anti-inflammatory activity .

HY-12076

BMS 777607 5+ Cited Publications BMS 817378	c-Met/HGFR TAM Receptor	Cancer
BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met, Axl, Ron and Tyro3 with IC₅₀s of 3.9 nM, 1.1 nM, 1.8 nM and 4.3 nM, respectively, and 40-fold more selective for Met-related targets than Lck, VEGFR-2, and TrkA/B, with more than 500-fold greater selectivity versus all other receptor and non receptor kinases .

HY-10209

Masitinib 5 Publications Verification AB1010	c-Kit PDGFR Src FGFR FAK Apoptosis	Cancer
Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), *Lck, and, to a lesser extent, FGFR3* and FAK. Masitinib (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-12010

BMS-599626 Hydrochloride 3 Publications Verification AC480 Hydrochloride	EGFR	Cancer
BMS-599626 Hydrochloride (AC480 Hydrochloride) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 Hydrochloride displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 Hydrochloride inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-11108

R406 free base 20+ Cited Publications	Syk FLT3 Apoptosis	Inflammation/Immunology Cancer
R406 free base is an orally available and competitive Syk/FLT3 inhibitor for ATP binding with a K_i of 30 nM, potently inhibits Syk kinase activity in vitro with an IC₅₀ of 41 nM, measured at an ATP concentration corresponding to its K_m value. R406 free base reduces immune complex-mediated inflammation . R406 free base also inhibits Lyn (IC₅₀=63 nM) and Lck (IC₅₀=37 nM) .

HY-10209A

Masitinib mesylate 5 Publications Verification AB-1010 mesylate	c-Kit PDGFR Src FGFR Apoptosis	Cancer
Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC₅₀=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC₅₀s=540/800 nM), Lyn (IC₅₀= 510 nM for LynB), *Lck, and, to a lesser extent, FGFR3* and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity .

HY-10251

BMS-599626 AC480	EGFR	Cancer
BMS-599626 (AC480) is a selective and orally bioavailable HER1 and HER2 inhibitor, with IC₅₀s of 20 and 30 nM, respectively. BMS-599626 displays ~8-fold less potent to HER4 (IC₅₀=190 nM), >100-fold to VEGFR2, c-Kit, Lck, MEK. BMS-599626 inhibits tumor cell proliferation, and has potential to increase tumor response to radiotherapy .

HY-112809

GSK2646264	Syk Src LRRK2 GSK-3 JAK VEGFR Aurora Kinase	Inflammation/Immunology
GSK2646264 (Compound 44) is a potent and selective spleen tyrosine kinase (SYK) inhibitor with a pIC₅₀ of 7.1. GSK2646264 also inhibits other kinases with pIC₅₀ values of 5.4, 5.4, 5.3, 5, 4.5, <4.6 and <4.3 against *LCK, LRRK2, GSK3β, JAK2, VEGFR2, Aurora B* and Aurora A, respectively. GSK2646264 is penetrable into the epidermis and dermis of the skin .

HY-15196

TAK-285 2 Publications Verification	EGFR	Cancer
TAK-285 is a potent, selective, ATP-competitive and orally active HER2 and EGFR(HER1) inhibitor with IC₅₀ of 17 nM and 23 nM, respectively. TAK-285 is >10-fold selectivity for HER1/2 than HER4, and less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc. TAK-285 has effective antitumor activity . TAK-285 can cross the blood-brain barrier (BBB) .

HY-10186

TG 100801 1 Publications Verification	VEGFR FGFR PDGFR Src	Cancer
TG 100801 is a proagent that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC₅₀s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively.

Cat. No.	Product Name	Type

HY-15764G

A 419259 (GMP) RK-20449 (GMP)	Fluorescent Dye
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC₅₀s of 9 nM, <3 nM, and <3 nM, respectively .

Cat. No.	Product Name	Type

HY-15764G

A 419259 (GMP) RK-20449 (GMP)	Biochemical Assay Reagents
A 419259 GMP is the GMP grade A 419259 (HY-15764), inducing cell apoptosis. GMP-grade small molecules can be used as auxiliary reagents in cell therapy. A 419259 (RK-20449) is a broad-spectrum pyrrole-pyrimidine inhibitor targeting Src, Lck, and Lyn with IC₅₀s of 9 nM, <3 nM, and <3 nM, respectively .

Cat. No.	Product Name	Target	Research Area

HY-P3279

EPQpYEEIPIYL 1 Publications Verification	Src	Cancer
EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains .

HY-P1377A

Caffeic acid-pYEEIE TFA

Src Inflammation/Immunology

Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

HY-P5438

Srctide	Peptides	Others
Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)

HY-P1377

Caffeic acid-pYEEIE

Src Inflammation/Immunology

Caffeic acid-pYEEIE, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain .

Species:	Human (2)
Tag:	Tag Free (1) GST (1)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P73269

	Lck Protein, Human (sf9, GST) Tyrosine-protein kinase LCK; LSK; LCK; Hck-3	Human	Sf9 insect cells
	The Lck protein is a non-receptor tyrosine protein kinase that is essential for T cell development and function. Lck is constitutively associated with CD4 and CD8 receptors and is recruited to the TCR/CD3 complex following TCR interaction with MHC. Lck Protein, Human (sf9, GST) is the recombinant human-derived Lck protein, expressed by Sf9 insect cells , with N-GST labeled tag. The total length of Lck Protein, Human (sf9, GST) is 509 a.a., with molecular weight of ~80 kDa.

HY-P702723

Lck Protein, Human (Biotinylated, sf9)

Tyrosine-protein kinase LCK; LSK; LCK; Hck-3
Human Sf9 insect cells

Cat. No.	Product Name	Application	Reactivity

HY-P80743

Lck Antibody (YA712) LCK; Tyrosine-protein kinase LCK; Leukocyte C-terminal Src kinase; LSK; Lymphocyte cell-specific protein-tyrosine kinase; Protein YT16; Proto-oncogene LCK; T cell-specific protein-tyrosine kinase; p56-LCK	WB	Human
Lck Antibody (YA712) is a non-conjugated and Mouse origined monoclonal antibody about 58 kDa, targeting to Lck (3E5). It can be used for WB assays with tag free, in the background of Human.

HY-P80747

Lyn Antibody (YA707) LYN; JTK8; Tyrosine-protein kinase Lyn; LCK/Yes-related novel protein tyrosine kinase; V-yes-1 Yamaguchi sarcoma viral related oncogene homolog; p53Lyn; p56Lyn	WB	Human
Lyn Antibody (YA707) is a non-conjugated and Mouse origined monoclonal antibody about 59 kDa, targeting to Lyn (1C8). It can be used for WB assays with tag free, in the background of Human.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

LCK

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products